BVS — Bioventus Inc.

Bioventus Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $132 million, up 7% year-over-year, slightly exceeding expectations.
• Adjusted EBITDA: $24 million, a 24% increase from the previous year, with an adjusted EBITDA margin of 18%, up 260 basis points.
• Adjusted EPS: $0.15, nearly double the $0.08 reported in Q1 2025.
• Cash Flow from Operations: $9 million, an increase of $28 million year-over-year, marking the largest cash flow from operations in the first quarter since becoming public.
• Debt: $272 million outstanding, reduced by $22 million during the quarter.

2. Strategic Updates and Business Highlights

• Bioventus is focusing on three priorities: accelerating long-term revenue growth, increasing earnings while investing in growth, and strengthening cash flow.
• Significant investments are being made in growth drivers: PNS (Peripheral Nerve Stimulation), PRP (Platelet-Rich Plasma), Ultrasonics, and the International segment.
• A dedicated general manager for PNS has been hired to enhance focus and execution.
• The company is expanding its sales and clinical teams and enhancing marketing efforts to raise awareness of its products.

3. Forward Guidance and Outlook

• Adjusted EPS Guidance: Raised to $0.75 to $0.79, up from previous guidance of $0.73 to $0.77.
• Cash Flow from Operations Guidance: Increased to $84 million to $89 million.
• Revenue Guidance: Reaffirmed at $600 million to $610 million for 2026, with expectations of accelerating growth in the second half of the year.

4. Bad News, Challenges, or Points of Concern

• While revenue growth was positive, there were headwinds, including reduced distributor inventory levels and one less selling day, which impacted volume growth in the Pain Treatments segment.
• The Surgical Solutions segment is tracking slightly below expectations, with plans for a ramp-up in growth anticipated in the second half of the year.
• There is a risk of margin fluctuations as investments ramp up throughout the year.

5. Notable Q&A Insights

• Management clarified that the favorable rebate adjustments were one-time events and do not anticipate similar variability moving forward.
• There is optimism regarding the early performance of new product launches (PNS and PRP), with expectations for growth to accelerate as investments continue.
• The company is focused on enhancing training for surgeons to maximize the adoption of Ultrasonics technology, which is seen as a key growth driver.
• Management indicated that they will provide more specific metrics on the performance of growth drivers later in the year as they gather more data on customer behavior and commercial activity.

Overall, Bioventus reported a strong start to 2026, with solid financial results and a clear strategy for growth, despite facing some operational challenges and market headwinds.